NCT01364688

Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

Randomized Control Trial of Oral Alfacalcidol and Coronary Artery Calcification in Predialysis Chronic Kidney Disease

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Ramathibodi Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Active vitamin D at therapeutic dose may prevent vascular calcification but in supraphysiologic dose may precipitate it.

Detailed description

Active vitamin D compound is used frequently in the treatment of hyperparathyroidism in chronic kidney disease. Recent evidence from animal studies suggested that low dose of active vitamin D may be protective against vascular calcification, whereas high dose could precipitate it. The present study will examine the effect of low dose oral alfacalcidol on coronary artery calcification in predialysis chronic kidney disease patients with hyperparathyroidism.

Conditions

• Vascular Calcification

Interventions

Type	Name	Description
DRUG	oral alfacalcidol	Oral alfacalcidol 0.5 microgram per day
DRUG	no drug	no drug

Timeline

• Start date: 2011-05-01
• Primary completion: 2012-11-01
• Completion: 2012-12-01
• First posted: 2011-06-02
• Last updated: 2011-06-02

Locations

1 site across 1 country: Thailand